Zeneca

Web3's biggest investors back social-fi innovation company /Reach in a bid to 'fix Crypto Twitter'

Retrieved on: 
Friday, December 15, 2023

NEW YORK, Dec. 15, 2023 /PRNewswire/ -- A group of the world's best known cryptocurrency and NFT investors are financially backing a new social-fi innovation company to 'fix Crypto Twitter'. The company, '/Reach', has attracted seed funding from a wide number of public facing figures including Seedphrase, Zeneca, Pranksy, Gmoney, Dingaling, and Mooncat2878. Previous institutional funding from amongst this group include investments in Blur, LooksRare, SuperRare, and NFTNow.

Key Points: 
  • NEW YORK, Dec. 15, 2023 /PRNewswire/ -- A group of the world's best known cryptocurrency and NFT investors are financially backing a new social-fi innovation company to 'fix Crypto Twitter'.
  • The company, '/Reach' , has attracted seed funding from a wide number of public facing figures including Seedphrase, Zeneca, Pranksy, Gmoney, Dingaling, and Mooncat2878.
  • We're here to change this, and we've built a fit-for-pupose protocol and gathered together some of the biggest names in crypto to help us achieve this mission."
  • The new company and its investors are looking to use social-fi innovation to fix some of the social media platform's most glaring problems.

Web3's biggest investors back social-fi innovation company /Reach in a bid to 'fix Crypto Twitter'

Retrieved on: 
Friday, December 15, 2023

NEW YORK, Dec. 15, 2023 /PRNewswire/ -- A group of the world's best known cryptocurrency and NFT investors are financially backing a new social-fi innovation company to 'fix Crypto Twitter'. The company, '/Reach', has attracted seed funding from a wide number of public facing figures including Seedphrase, Zeneca, Pranksy, Gmoney, Dingaling, and Mooncat2878. Previous institutional funding from amongst this group include investments in Blur, LooksRare, SuperRare, and NFTNow.

Key Points: 
  • NEW YORK, Dec. 15, 2023 /PRNewswire/ -- A group of the world's best known cryptocurrency and NFT investors are financially backing a new social-fi innovation company to 'fix Crypto Twitter'.
  • The company, '/Reach' , has attracted seed funding from a wide number of public facing figures including Seedphrase, Zeneca, Pranksy, Gmoney, Dingaling, and Mooncat2878.
  • We're here to change this, and we've built a fit-for-pupose protocol and gathered together some of the biggest names in crypto to help us achieve this mission."
  • The new company and its investors are looking to use social-fi innovation to fix some of the social media platform's most glaring problems.

Catalent Appoints David McErlane as Biologics Segment Leader

Retrieved on: 
Monday, September 18, 2023

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent’s Biologics segment, effective September 25, 2023.

Key Points: 
  • Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent’s Biologics segment, effective September 25, 2023.
  • Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza’s Bioscience business.
  • Prior to joining Lonza, Mr. McErlane held several leadership positions at MilliporeSigma and BioReliance after beginning his career as an engineering manager at Zeneca.
  • “David is a seasoned and highly successful business leader with a record of developing winning strategies that drive growth and create significant value,” said Alessandro Maselli, President and Chief Executive Officer of Catalent.

SIRPant Immunotherapeutics Appoints Jelle Kijlstra, MD, MBA as Chief Medical Officer

Retrieved on: 
Tuesday, July 11, 2023

SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Jelle Kijlstra, MD, MBA as its new Chief Medical Officer.

Key Points: 
  • SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Jelle Kijlstra, MD, MBA as its new Chief Medical Officer.
  • Most recently, he was CMO at Sound Biologics, an antibody engineering company that develops checkpoint inhibitor combination therapy.
  • Dr. Kijlstra received his medical degree (MD) and hematology training from the University of Amsterdam (Netherlands) and his MBA from Northwestern University (Chicago), where he was the Henry J. Kaiser Family Foundation Scholar in Health Policy.
  • I am intrigued by this potential as well as the opportunity to advance our SIRPant-M™ program into solid tumors, initially focusing on head & neck cancers.”

IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model

Retrieved on: 
Wednesday, June 7, 2023

IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy.

Key Points: 
  • IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy.
  • IFF expects its new operating model to be in effect by the beginning of 2024.
  • As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating model is in full effect in the new year.
  • “Our evolution to a category-aligned operating model is a pivotal moment for IFF,” said Frank Clyburn, IFF CEO.

Zura Bio Announces Appointment of Chief Scientific Officer

Retrieved on: 
Friday, April 14, 2023

Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science.

Key Points: 
  • Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science.
  • Dr. Howell brings more than two decades of experience leading discovery, translational research, and early clinical programs and will lead the scientific strategy and translational science efforts at Zura Bio.
  • “I am thrilled to have Michael Howell join our team as our Chief Scientific Officer and Head of Translational Science,” said Someit Sidhu, M.D., CEO of Zura Bio.
  • He formerly served as the Chief Scientific Officer of DermTech, Inc.

Providence Therapeutics Appoints Robert Georgantas, Ph.D. as President and Chief Technology Officer

Retrieved on: 
Wednesday, February 1, 2023

CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced the appointment of Robert Georgantas III, Ph.D., as President and chief technology officer (CTO).

Key Points: 
  • CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced the appointment of Robert Georgantas III, Ph.D., as President and chief technology officer (CTO).
  • “Robert’s experience in drug discovery, clinical development, and management at the executive level across several biotech and large pharmaceutical companies will be invaluable as we continue advancing our pipeline of mRNA vaccines,” said Brad Sorenson, MBA, chief executive officer of Providence Therapeutics.
  • He additionally contributed to clinical development and medical affairs activities, participating in the design and statistical analysis of multiple clinical studies.
  • Dr. Georgantas received his Ph.D. at the Johns Hopkins University School of Medicine and his master’s degree in Cellular Biology at the Illinois Institute of Technology.

Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

Retrieved on: 
Wednesday, January 4, 2023

Fort Lee, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a collaboration with the European Network of Gynecological Oncology Trial Groups (“ENGOT”) and the GOG Foundation, Inc. (“GOG-F”) to conduct the NXP800 Phase 1b clinical trial in ARID1A-mutated, ovarian clear cell and endometroid carcinomas in Europe and the United States.

Key Points: 
  • Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead
    Dr. Shannon Westin (MD Anderson Cancer Center, Houston, TX) and Dr. Ramez Eskander (University of California San Diego, San Diego, CA) will be the co-GOG Foundation Trial Leads in the US
    Fort Lee, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a collaboration with the European Network of Gynecological Oncology Trial Groups (“ENGOT”) and the GOG Foundation, Inc. (“GOG-F”) to conduct the NXP800 Phase 1b clinical trial in ARID1A-mutated, ovarian clear cell and endometroid carcinomas in Europe and the United States.
  • “We are honored to collaborate with the ENGOT and GOG-F on this very important clinical trial.
  • ENGOT and GOG-F are the world's premier gynecology oncology clinical trials consortia, representing some of the leading medical centers and having spear-headed several drug approvals in the field, including the 2 PARP inhibitors for the treatment of BRCA-mutated ovarian cancers, Olaparib (Astra Zeneca) and Niraparib (GSK), as well as the antibody-drug conjugate Tivdak (Seattle Genetics), which is approved for cervical cancer,” said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis.
  • Clinical data from the ongoing Phase 1a trial to date suggest that the emerging clinical profile of NXP800 can provide a good balance between systemic exposure, pharmacodynamic activity and tolerability, and we look forward to the initiation of the Phase 1b trial in the next few months.”

Timex Goes Ape

Retrieved on: 
Thursday, December 1, 2022

MIDDLEBURY, Conn., Dec. 1, 2022 /PRNewswire/ -- Timex®, the #1 selling watch brand in the United States*, is going bananas over its partnership with select community members involved in one of the world's biggest NFT projects, the Bored Ape Yacht Club.  Timex, the watch of the metaverse, enters Web3, with a first-ever collection of ultra-rare one-of-one timepieces and corresponding digital twin NFTs, exclusively available to members of the Bored Ape and Mutant Ape community. 

Key Points: 
  • Timex, the watch of the metaverse, enters Web3, with a first-ever collection of ultra-rare one-of-one timepieces and corresponding digital twin NFTs, exclusively available to members of the Bored Ape and Mutant Ape community.
  • Developed in partnership with long-term ape holders, each stunning, custom created digital collectible and hand assembled watch is based on the iconic Timex Waterbury Classic design to showcase the Ape or Mutant on full display.
  • Creative direction, design and Web3 utility for the Timex Goes Ape project was consulted by Josh Ong , CryptoVonDoom , The Miami Ape , LOGIK , BaronVonHustle and Zeneca , long-time Bored Ape holders who have been in the club since the beginning, when Yuga Labs first launched the collection.
  • Timex teamed up with best-in-class partners to Go Ape including Daz3D, a leader in web3 strategy, marketing, and full-stack development, as well as long-term Bored Ape members.

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Retrieved on: 
Thursday, September 15, 2022

BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”) and Cend Therapeutics, Inc. (“Cend”) today announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc. (“Lisata”) and will focus primarily on advancing its CendR Platform™ technology product candidates in a range of oncology indications, in addition to Caladrius’ existing development programs. Lisata will commence trading on The Nasdaq Capital Market today, September 15, 2022, under the ticker symbol “LSTA”.

Key Points: 
  • Lisatas cash and investments, as of immediately following the closing of the merger, are approximately $76 million.
  • Prior to the closing of the merger, Caladrius effected a 1-for-15 reverse split of its common stock.
  • Pursuant to the merger agreement and upon the closing of the merger, three former Cend directors, including Erkki Ruoslahti, M.D., Ph.D., Heidi Henson, and David Slack, MBA, were appointed as directors.
  • Additionally, Lisata is pleased to announce that Mohammad Azab, M.D., M.Sc., MBA has been appointed to the Lisata Board of Directors.